Navigation Links
Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease

BALTIMORE, Sept. 19 /PRNewswire/ -- Alba Therapeutics Corporation today announced that it has dosed its first patient in a six-week Phase IIb trial with oral AT-1001, an inhibitor of gastrointestinal barrier dysfunction, for the maintenance of remission in patients with Celiac Disease (CD). The multi-center, double-blind, placebo-controlled, dose ranging study will evaluate the efficacy, safety and tolerability of AT-1001 in CD subjects during a six-week gluten challenge, while also testing components of a Celiac Disease activity rating index, a new patient-reported outcomes instrument. "This is Alba's fifth human trial with AT-1001 and highlights our efforts to develop paradigms for the treatment of CD and for the assessment of activity in this neglected disease" stated Dr. Blake Paterson, CEO of Alba. "Since there is no effective treatment for CD and no validated means of measuring disease progression, the successful completion of this study will be a tremendous step forward for Celiac patients."

About Celiac Disease

Celiac Disease ("CD") is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.

About AT-1001

AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through some unknown inhibitory, direct effect on gastrointestinal associated lymphoid tissue. AT-1001 is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of Celiac Disease, and is also being evaluated for the treatment of Type 1 Diabetes and Crohn's Disease. Results of the Company's first study in celiac patients are available online at: .x

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory disease, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body.

Contact: Bernard McDonald, PhD

Phone: 410-319-0780


Web site:

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:10/12/2015)... Leadership of the National Association of Vision Care ... Aspasia Shappet , CEO of MESVision resumed her role as ... at its annual strategic planning meeting in Chicago ... the organization from May 2013 to May of this year. ... a result of the increased demands of his recent appointment ...
(Date:10/12/2015)... , Oct. 12, 2015 A new computer ... children can predict whether they will develop effective language ... to a study in the journal Brain and ... --> In the journal,s Oct. 12 online edition, ... computer program determines how specific regions of the brain ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
Breaking Medicine Technology:
(Date:10/12/2015)... Grove Village, IL, USA (PRWEB) , ... October ... ... solutions and high-fidelity personal audio products, will present the latest version of Companion ... insert earphones for audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) ...
(Date:10/12/2015)... ... October 12, 2015 , ... FEI Behavioral Health, ... from EAP to crisis management, will present a session at the Wisconsin Society ... 14-16, 2015. , FEI’s Chief Operating Officer Daniel Potterton will present an informative ...
(Date:10/12/2015)... FL (PRWEB) , ... October 12, 2015 , ... ... Awareness Month, IQ Formulations today announced its charitable donation to the National Breast ... inspiring hope in those affected by breast cancer through early detection, education, and ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group is proud ... contact channel benchmarking study. Be a part of this insightful and leading-edge ... customer experience, customer journey, contact channel execution and intelligence, workforce optimization, and tools ...
(Date:10/12/2015)... ... October 12, 2015 , ... Holcomb – Kreithen Plastic ... in Florida, announced today that it will host “Plastic Surgery University,” an educational series ... Town Center (“UTC Mall”) in Sarasota, FL on Saturday, October 24, 2015. , ...
Breaking Medicine News(10 mins):